Ignite Creation Date:
2025-12-25 @ 2:48 AM
Ignite Modification Date:
2026-06-24 @ 8:38 AM
Study NCT ID:
NCT05322733
Status:
UNKNOWN
Last Update Posted:
2022-04-19
First Post:
2022-03-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | View |
Keywords: